A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

NCT02533453 on ClinicalTrials.gov · last registry update 2019-05-31

Finished 7 December 2016, after enrolling 110 people. Primary outcome, as filed: Percentage of Participants With Adverse Events(AEs) and Serious Adverse Event(SAEs). exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 110
Started: 2016-01-28
Primary completion: 2016-12-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage of Participants With Adverse Events(AEs) and Serious Adverse Event(SAEs)

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.